Galapagos (GLPG) Expected to Announce Earnings on Wednesday

Galapagos (NASDAQ:GLPG) is expected to post its quarterly earnings results after the market closes on Wednesday, April 23rd. Analysts expect Galapagos to post earnings of ($0.19) per share and revenue of $72.22 million for the quarter.

Galapagos Price Performance

Shares of NASDAQ:GLPG opened at $23.88 on Wednesday. The business has a 50-day simple moving average of $25.28 and a two-hundred day simple moving average of $26.40. Galapagos has a fifty-two week low of $22.36 and a fifty-two week high of $31.23.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on GLPG shares. Morgan Stanley cut Galapagos from an “equal weight” rating to an “underweight” rating and decreased their price target for the company from $31.00 to $22.00 in a report on Friday, February 14th. Barclays restated an “underweight” rating on shares of Galapagos in a research report on Thursday, January 23rd. Finally, TD Cowen downgraded Galapagos from a “strong-buy” rating to a “strong sell” rating in a report on Thursday, January 9th. Four investment analysts have rated the stock with a sell rating and four have given a hold rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $25.33.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.